Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of DPH001 vs Nexavar in Healthy Volunteers
NCT06797427Phase 1Completed
- Sponsor
- Disruptive Pharma
- Start
- Feb 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Sorafenib MMC in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid cancer (2 arms), sponsored by Disruptive Pharma. Primary endpoints: Area Under the Curve (0-6h), Area Under the Curve (0-72h) and 3 more. Started Feb 2025; status: completed.
02
Drugs
Sorafenib MMC
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)thyroid cancer
Beyond the preview
Go deeper on NCT06797427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797427.